PCM
CRL icon

Prelude Capital Management’s Charles River Laboratories CRL Stock Holding History

Prelude Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,500
Closed -$321K – 1626
2022
Q2 		$321K Hold
1,500
– – 0.01% 1032
2022
Q1 		$426K Buy
+1,500
New +$463K 0.01% 926

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Prelude Capital Management's CRL Position: Q1 2026 in Review

Prelude Capital Management increased its Charles River Laboratories (CRL) stake by 3.9% in Q1 2026, buying an estimated $8.34K and bringing the position to 1,204 shares worth $208K. The position accounts for 0.02% of the portfolio, ranked #898.

Prelude Capital Management first reported a position in CRL in Q3 2013 and has held it in 23 quarters since. The position peaked at $1.83M in Q1 2024. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Prelude Capital Management held 1,204 shares of Charles River Laboratories worth $208K as of Q1 2026.
  • Prelude Capital Management bought 45 Charles River Laboratories shares in Q1 2026, an estimated $8.34K.
  • Charles River Laboratories made up 0.02% of Prelude Capital Management's portfolio in Q1 2026, its #898 holding.
  • Prelude Capital Management first reported a position in Charles River Laboratories in Q3 2013 and has held it in 23 quarters since.
  • Prelude Capital Management's Charles River Laboratories position peaked at $1.83M in Q1 2024.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.